Comparisons of alloreactive potential of clinical hematopoietic grafts

Wing Leung, Manuel Ramírez, Goutam Mukherjee, Elizabeth J. Perlman, Curt I. Civin

Research output: Contribution to journalArticle

Abstract

Background. We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients. Methods. Forty mice were randomized to receive a range of doses of T cell-replete cell preparations from one of the above three cell sources. Twenty-eight control mice underwent transplantation with T cell-depleted cells. Mice were observed for 60 days for the development of fatal xenogeneic graft-versus-host disease-like syndrome (GVHDLS). Results. For the mice that had received T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for the number of T cells transplanted, the relative hazard of developing fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB. Flow cytometric and histologic analyses of selected chimeras that died of GVHDLS showed extensive proliferation of human T cells in multiple organs. In contrast, mice that survived to day 60 were engrafted with human myeloid and B lymphoid cells. Conclusions. The immunoreactive potential, as measured by this in vivo assay, differed among clinical grafts: BM > PBSC > CB.

Original languageEnglish (US)
Pages (from-to)628-635
Number of pages8
JournalTransplantation
Volume68
Issue number5
DOIs
StatePublished - Sep 15 1999

Fingerprint

Graft vs Host Disease
T-Lymphocytes
Transplants
Fetal Blood
Bone Marrow
Transplantation
Lymphocytes
Survival
Neoplasms

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Leung, W., Ramírez, M., Mukherjee, G., Perlman, E. J., & Civin, C. I. (1999). Comparisons of alloreactive potential of clinical hematopoietic grafts. Transplantation, 68(5), 628-635. https://doi.org/10.1097/00007890-199909150-00006

Comparisons of alloreactive potential of clinical hematopoietic grafts. / Leung, Wing; Ramírez, Manuel; Mukherjee, Goutam; Perlman, Elizabeth J.; Civin, Curt I.

In: Transplantation, Vol. 68, No. 5, 15.09.1999, p. 628-635.

Research output: Contribution to journalArticle

Leung, W, Ramírez, M, Mukherjee, G, Perlman, EJ & Civin, CI 1999, 'Comparisons of alloreactive potential of clinical hematopoietic grafts', Transplantation, vol. 68, no. 5, pp. 628-635. https://doi.org/10.1097/00007890-199909150-00006
Leung, Wing ; Ramírez, Manuel ; Mukherjee, Goutam ; Perlman, Elizabeth J. ; Civin, Curt I. / Comparisons of alloreactive potential of clinical hematopoietic grafts. In: Transplantation. 1999 ; Vol. 68, No. 5. pp. 628-635.
@article{4dbc93506ca246d4b1be2b559dfb6afd,
title = "Comparisons of alloreactive potential of clinical hematopoietic grafts",
abstract = "Background. We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients. Methods. Forty mice were randomized to receive a range of doses of T cell-replete cell preparations from one of the above three cell sources. Twenty-eight control mice underwent transplantation with T cell-depleted cells. Mice were observed for 60 days for the development of fatal xenogeneic graft-versus-host disease-like syndrome (GVHDLS). Results. For the mice that had received T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for the number of T cells transplanted, the relative hazard of developing fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB. Flow cytometric and histologic analyses of selected chimeras that died of GVHDLS showed extensive proliferation of human T cells in multiple organs. In contrast, mice that survived to day 60 were engrafted with human myeloid and B lymphoid cells. Conclusions. The immunoreactive potential, as measured by this in vivo assay, differed among clinical grafts: BM > PBSC > CB.",
author = "Wing Leung and Manuel Ram{\'i}rez and Goutam Mukherjee and Perlman, {Elizabeth J.} and Civin, {Curt I.}",
year = "1999",
month = "9",
day = "15",
doi = "10.1097/00007890-199909150-00006",
language = "English (US)",
volume = "68",
pages = "628--635",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Comparisons of alloreactive potential of clinical hematopoietic grafts

AU - Leung, Wing

AU - Ramírez, Manuel

AU - Mukherjee, Goutam

AU - Perlman, Elizabeth J.

AU - Civin, Curt I.

PY - 1999/9/15

Y1 - 1999/9/15

N2 - Background. We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients. Methods. Forty mice were randomized to receive a range of doses of T cell-replete cell preparations from one of the above three cell sources. Twenty-eight control mice underwent transplantation with T cell-depleted cells. Mice were observed for 60 days for the development of fatal xenogeneic graft-versus-host disease-like syndrome (GVHDLS). Results. For the mice that had received T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for the number of T cells transplanted, the relative hazard of developing fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB. Flow cytometric and histologic analyses of selected chimeras that died of GVHDLS showed extensive proliferation of human T cells in multiple organs. In contrast, mice that survived to day 60 were engrafted with human myeloid and B lymphoid cells. Conclusions. The immunoreactive potential, as measured by this in vivo assay, differed among clinical grafts: BM > PBSC > CB.

AB - Background. We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (peripheral blood stem cells; PBSC) from cancer patients. Methods. Forty mice were randomized to receive a range of doses of T cell-replete cell preparations from one of the above three cell sources. Twenty-eight control mice underwent transplantation with T cell-depleted cells. Mice were observed for 60 days for the development of fatal xenogeneic graft-versus-host disease-like syndrome (GVHDLS). Results. For the mice that had received T cell-replete grafts of CB or BM or PBSC, the duration of GVHDLS free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for the number of T cells transplanted, the relative hazard of developing fatal GVHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared with CB. Flow cytometric and histologic analyses of selected chimeras that died of GVHDLS showed extensive proliferation of human T cells in multiple organs. In contrast, mice that survived to day 60 were engrafted with human myeloid and B lymphoid cells. Conclusions. The immunoreactive potential, as measured by this in vivo assay, differed among clinical grafts: BM > PBSC > CB.

UR - http://www.scopus.com/inward/record.url?scp=0344678346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344678346&partnerID=8YFLogxK

U2 - 10.1097/00007890-199909150-00006

DO - 10.1097/00007890-199909150-00006

M3 - Article

C2 - 10507480

AN - SCOPUS:0344678346

VL - 68

SP - 628

EP - 635

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 5

ER -